Insulin Glulisine
Recommended EndocrinologyUnrestricted
Treatment of Type 1 and Type 2 diabetes mellitus in adults and children older than 12 years who require insulin for the control of hyperglycaemia.
2
Submissions
2007–07
On the record
—
ICER range
Cost-min
Cost basis
Decision on record
- Meeting Jul 2008 Recommended Diabetes no PSD
Access path
- Mar 2007Recommended
Evidence: RCT, Meta-analysis → RCT
- Mar 2007Recommended
Evidence: RCT, Meta-analysis → RCT
- PBS listing · Unrestricted
RecommendedDeferredNot recommended
Cost-effectiveness
Cost-minimisation analysis; no ICER calculated by design.
The PBAC agreed that the choice of a cost-minimisation approach was valid and that the equi-effective doses in this context were insulin glulisine 100 IU/mL and insulin lispro 100 IU/mL. PBAC · 2007
Decision context
PopulationAdults and children older than 12 years with Type 1 or Type 2 diabetes mellitus requiring insulin for the control of hyperglycaemia.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2007 | Recommended | insulin lispro | — | RCT, Meta-analysis · HbA1c reduction |
| Mar 2007 | Recommended | insulin lispro | — | RCT · HbA1c |